- Home
- ABT vs MRK Comparison
ABT vs MRK Comparison
Compare ABT & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABT | MRK |
|---|---|---|
| Founded | 1888 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.6B | 268.7B |
| IPO Year | 2006 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ABT | MRK |
|---|---|---|
| Price | $109.95 | $116.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 14 |
| Target Price | ★ $141.00 | $123.21 |
| AVG Volume (30 Days) | 7.4M | ★ 9.7M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | 2.27% | ★ 2.93% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | 3.72 | ★ 7.28 |
| Revenue | $44,328,000,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $8.92 | $3.74 |
| Revenue Next Year | $7.39 | $5.47 |
| P/E Ratio | $29.80 | ★ $15.93 |
| Revenue Growth | ★ 5.67 | 1.31 |
| 52 Week Low | $105.27 | $75.40 |
| 52 Week High | $139.15 | $125.14 |
Technical Indicators
Market Signals| Indicator | ABT | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 37.45 | 45.35 |
| Support Level | $105.27 | $105.23 |
| Resistance Level | $113.76 | $125.14 |
| Average True Range (ATR) | 1.85 | 2.77 |
| MACD | -0.03 | -1.17 |
| Stochastic Oscillator | 17.82 | 19.08 |
Price Performance
Historical ComparisonAbout ABT Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).